Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Separately, a Delaware jury in late October found that Masimo’s current products did not infringe any of Apple’s patents. The ...

Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

4 analysts have expressed a variety of opinions on Masimo MASI over the past quarter ... remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

A Delaware jury has ruled in favor of Apple Inc. (NASDAQ:AAPL) in a patent infringement case against Masimo Corp.

markets sells and licenses premium and luxury audio sound products and related integration technologies. Understanding the Numbers: Masimo's Finances Market Capitalization Analysis: The company's ...

that one of Apple’s technology patent claims is invalid and that no current Masimo product infringed any of Apple’s design patents,” said a statement from Masimo. “Although the jury found that a ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

“Apple primarily sought an injunction against Masimo’s current products, and the jury’s verdict is a victory for Masimo on that issue,” Masimo said. Apple said in a statement that it was ...